Haemonetics’ $435 Million Convertible Notes Offering

Latham & Watkins LLP represented the initial purchasers in the offering.

Haemonetics Corporation (NYSE: HAE) priced its offering of US$435 million aggregate principal amount of 0% Convertible Senior Notes due 2026 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The offering size was increased from the previously announced offering size of US$425 million aggregate principal amount of notes. 

The initial purchasers included Citigroup Global Markets Inc., J.P. Morgan Securities LLC, BofA Securities, Inc., Goldman Sachs & Co. LLC, U.S. Bancorp Investments, Inc., Citizens Capital Markets, Inc., CJS Securities, Inc., HSBC Securities (USA) Inc., MUFG Securities Americas Inc., Raymond James & Associates, Inc. and TD Securities (USA) LLC.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare.

Latham & Watkins LLP represented the initial purchasers in the offering with a capital markets team led by Boston/New York partner Wesley Holmes (Picture) and New York partner Reza Mojtabaee-Zamani, with New York associates Eric Rice, Marc Langer, Kate Kim, and Paul Rafla. Advice was also provided on tax matters by New York partner Elena Romanova, with New York associate Michael Syku.

Involved fees earner: Wesley Holmes – Latham & Watkins; Katherine Kim – Latham & Watkins; Marc Langer – Latham & Watkins; Reza Mojtabaee-Zamani – Latham & Watkins; Paul Rafla – Latham & Watkins; Eric Rice – Latham & Watkins; Elena Romanova – Latham & Watkins; Michael Syku – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Bank of America Securities; Citigroup Global Markets Ltd; Citizens Capital Markets; CJS Securities; Goldman Sachs & Co.; HSBC Securities; J.P. Morgan Securities LLC; MUFG Securities Americas Inc. ; Raymond James & Associates, Inc.; TD Securities; U.S. Bancorp Investments;

Author: Martina Bellini